Meta-Analysis Research to Discover Novel Method for Increasing the Role of NK Cells in LAG-3 Immunotherapy to Increase Efficiency of Melanoma Treatment
Session Number
Project ID: RISE 08
Advisor(s)
Mrs. Allison Hennings, Illinois Mathematics and Science Academy
Dr. Munirathinam Gnanasekaran (Ph.D.), University of Chicago at Illinois, Biomedical Science
Dr. Anandaraman Veerapathran (Ph.D), Obsidian Biotherapeutics
Dr. Krithika Kodumundi (Ph.D.), Iovance Biotherapeutics
Discipline
Medical and Health Sciences
Start Date
17-4-2024 10:25 AM
End Date
17-4-2024 10:40 AM
Abstract
The purpose of this meta-analysis was to determine the efficiency and stability of introducing natural killer (NK) cells in the existing immunotherapy for melanoma cancer known as LAG-3 CD223. NK cells are already in use for HIV immunotherapy, however, are not available in current cancer treatments. Including NK cells can allow the body to develop a natural means to attack the cancer cells and use additional immune responses to defend the body.The procedure started by taking the data from existing research done on the LAG-3 checkpoint and the logistics of immunotherapy at this location. The independent variable was the presence or absence of NK cells and the variable being tested was the change in success rate of the immunotherapy. The melanoma treatment which lacks the use of NK cells was compared to HIV immunotherapy which uses NK cells. The change in success rate allows for the true effect of the NK cells in immunotherapy to be analyzed. Overall, the use of NK cells in LAG-3 CD223 demonstrated positive performance and rejection of the null hypothesis based on the statistical significance of the one-way ANOVA test (p
Meta-Analysis Research to Discover Novel Method for Increasing the Role of NK Cells in LAG-3 Immunotherapy to Increase Efficiency of Melanoma Treatment
The purpose of this meta-analysis was to determine the efficiency and stability of introducing natural killer (NK) cells in the existing immunotherapy for melanoma cancer known as LAG-3 CD223. NK cells are already in use for HIV immunotherapy, however, are not available in current cancer treatments. Including NK cells can allow the body to develop a natural means to attack the cancer cells and use additional immune responses to defend the body.The procedure started by taking the data from existing research done on the LAG-3 checkpoint and the logistics of immunotherapy at this location. The independent variable was the presence or absence of NK cells and the variable being tested was the change in success rate of the immunotherapy. The melanoma treatment which lacks the use of NK cells was compared to HIV immunotherapy which uses NK cells. The change in success rate allows for the true effect of the NK cells in immunotherapy to be analyzed. Overall, the use of NK cells in LAG-3 CD223 demonstrated positive performance and rejection of the null hypothesis based on the statistical significance of the one-way ANOVA test (p